Tamtam Try Tamtam free
Merck Group logo

Merck Group account plan

Healthcare lifescience electronics solutions

At a glance

Merck KGaA is a family-controlled German science and technology group in Life Science, Healthcare and Electronics, with €21,102 million of 2025 sales.

Merck KGaA, Darmstadt, Germany, is a science and technology company founded in 1668 that works in three sectors: Life Science, Healthcare and Electronics. In the US and Canada it operates as MilliporeSigma, EMD Serono and EMD Electronics. In FY2025 it reported net sales of €21,102 million (organic +3.1%), EBITDA pre of €6,109 million (28.9% margin) and profit after tax of €2,615 million; Asia-Pacific (€6,936 million) and Europe (€6,417 million) were its largest regions. It had 62,461 employees at 31 December 2025 and 62,136 at 30 June 2026. The founding family holds 70.274% via E. Merck KG, and 29.726% of the share capital is listed in Frankfurt; Kai Beckmann has been Group CEO since 1 May 2026.

Business units

Strategic priorities

Three growth drivers
Process Solutions, Rare Diseases and Semiconductor Solutions are positioned to generate up to 80% of growth in the medium term, with mid-single-digit organic sales growth targeted.
New strategic direction (May 2026)
Four streams: focus on high-growth value drivers, shift selected portfolios to integrated workflow solutions, platform capabilities across businesses such as AI deployment, and sourcing innovation through M&A and in-licensing.
Integrated workflow solutions
Merck is moving selected portfolios from standalone products to end-to-end offerings, as in bioprocessing (consumables, bioreactors, process analytics software) and in materials plus metrology for advanced chips.
Healthcare pipeline and margin
Healthcare stays above a 30% EBITDA pre margin while R&D moves towards 25% of sales, with pipeline building focused on early and mid-stage external innovation.
Sustainability
Climate neutrality by 2040; Scope 1 and 2 emissions are down 60% versus 2020, with renewable purchased electricity at 64% toward 80% by 2030.

Latest results

In H1 2026 net sales were €10,568 million (+0.3%; organic +3.5%) and EBITDA pre €3,129 million (+4.4%; organic +7.2%), a 29.6% margin; free cash flow rose to €565 million from €194 million. Q2 2026 sales grew 4.1% organically to €5,434 million, while EBIT fell 15.5% to €753 million on €189 million of restructuring expenses. Life Science and Electronics grew organically while Healthcare declined on US Mavenclad generics. Guidance was raised for the second time to net sales of €21.0-21.8 billion, EBITDA pre of €5.9-6.3 billion and EPS pre of €7.90-8.60. Net financial debt was €9,207 million at 30 June 2026.

Investments and deals

Bio-Techne acquisition
Agreed on 25 June 2026 at US$73 per share, a company value of around US$11.3 billion (€9.9 billion); close expected end-2026/early 2027, with run-rate cost synergies of approximately €140 million by year three.
SpringWorks Therapeutics
Acquired on 1 July 2025 for an enterprise value of approximately €3 billion, creating the Rare Diseases franchise (Ogsiveo, Gomekli/Ezmekly).
JSR chromatography business
Acquisition of JSR Corporation's chromatography business (Amsphere Protein A resins) completed in March 2026.
Manufacturing sites
Over €7 billion invested in over 30 new or expanded sites since 2021, including the €500 million Kaohsiung megasite in Taiwan and a €150 million filter plant at Blarney, Cork.
Surface Solutions divestment
Pigments business sold to Global New Material International Holdings for €669 million, closed 31 July 2025.

Challenges and risks

Mavenclad generics in the US
Two US dosing-regimen patents were held invalid, opening the market to generics; 2026 guidance assumes no US Mavenclad sales from August 2026.
Currency headwinds
Currency effects cut FY2025 sales by 3.7%, pushing sales below the original guidance.
Geopolitics and supply chain
Risks include Russia-Ukraine, the Taiwan Strait, US-China export controls, and the Gulf conflict and Strait of Hormuz for supply chains and raw materials.
Pricing and competition
Drug pricing pressure, overcapacity and price pressure in bioprocessing, semiconductor cyclicality and Chinese competition are listed among the most significant risks.
Weak lab and consumer electronics demand
US policy changes affecting academic and government labs and a weak China held Science & Lab Solutions flat, and weak consumer electronics hit Optronics.

What leadership says

“only a clear plan and disciplined execution will move us closer to the sustainable, profitable growth we are building for our company.”

Kai Beckmann, Chairman of the Executive Board and Group CEO · Q2 2026 investor and analyst call, 6 August 2026

“In short, we will optimize for speed and scalability where it matters.”

Kai Beckmann, Chairman of the Executive Board and Group CEO · Q1 2026 call with strategic direction update, 13 May 2026

“Most importantly, we transform in times of growth.”

Belén Garijo, Chair of the Executive Board and CEO · Semafor Signal Interview, 14 November 2025

Where a supplier can help

Bio-Techne integration
Integration is the stated priority after the Bio-Techne deal, with about €140 million of cost synergies targeted, a fit for integration, systems and process consultancies.
AI platform capabilities
AI deployment is one of the shared platform capabilities in the new strategic direction, opening doors for data, AI and digital workflow suppliers.
Integrated workflow offerings
The shift from standalone products to end-to-end offerings in bioprocessing and chip materials creates room for software, analytics and equipment partners.
New plant start-ups
Startup of new sites such as Blarney in Ireland and Kaohsiung in Taiwan, and the move from building to loading capacity, needs automation, maintenance and operations support.
Supply-chain resilience
Geopolitical and Strait of Hormuz supply-chain risks point to demand for sourcing, logistics and raw-material risk services.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Merck Group?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Merck Group

What does Merck KGaA do?

Merck KGaA, Darmstadt, Germany, is a science and technology company in Life Science, Healthcare and Electronics, operating in the US and Canada as MilliporeSigma, EMD Serono and EMD Electronics.

What was Merck KGaA's revenue in 2025?

Net sales were €21,102 million in FY2025, with EBITDA pre of €6,109 million and profit after tax of €2,615 million.

How many employees does Merck KGaA have?

It had 62,461 employees at 31 December 2025 and 62,136 at 30 June 2026.

Who leads Merck KGaA?

Kai Beckmann became Chairman of the Executive Board and Group CEO on 1 May 2026, succeeding Belén Garijo; Helene von Roeder is CFO.

What is Merck KGaA's strategy?

It focuses on three growth drivers (Process Solutions, Rare Diseases, Semiconductor Solutions), integrated workflow solutions and M&A such as the Bio-Techne deal, targeting mid-single-digit organic growth.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)